tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Cell Encapsulation'

PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology

PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology

Written by Ι Stock Market Media — June 6, 2018

PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world, the U.S. Food and Drug Administration (FDA).  It would be the company’s first clinical trial ever and could serve as the event that changes the way solid cancerous tumors are treated, ...

Read More →
0

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

SILVER SPRING, Md., Jan. 06, 2016 — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 ...

Read More →
0

Nuvilex Secures Worldwide License for Insulin-Producing Cells for Use in Developing Diabetes Treatment

SILVER SPRING, Md., Oct. 16, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into a license with the University of Technology in Sydney, Australia (UTS), that grants Nuvilex the worldwide rights to use human insulin-producing cells, termed “Melligen” cells, developed by Prof. Ann Simpson and her colleagues at UTS for the development of a treatment for insulin-dependent (Type 1 or ...

Read More →
0

Nuvilex Appoints Dr. Matthias Lohr as Chairman of Scientific Advisory Board

SILVER SPRING, MD., Oct. 6, 2014 — Nuvilex, Inc.Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that noted European gastroenterologist and oncologist Dr. Matthias Lohr has agreed to serve as Chairman of Nuvilex’s newly formed Scientific Advisory Board.

Dr. Lohr has been a full professor of gastroenterology and hepatology at the famed Karolinska Institute in Stockholm, Sweden, since 2007. He has served as Professor of Molecular Gastroenterology at the University ...

Read More →
0

Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market

Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market

Written by ι Stock Market Media Group Staff — July 7, 2014

Nuvilex, Inc. (OTCQB: NVLX) announced last week that its executives recently met with the company’s “global development partners” at the 2014 BIO International Convention in San Diego.  One of the meetings that CEO Ken Waggoner and COO Dr. Gerald Crabtree held was with a representative of the Juvenile Diabetes Research Foundation (JDRF) to discuss Nuvilex’s plans for treating diabetes.  This, of course, begs the question − is Nuvilex in line for ...

Read More →
0

Nuvilex Funding Has Investors Preparing for Milestone Announcements in Late-Phase Clinical Trials

Nuvilex Funding Has Investors Preparing for Milestone Announcements in Late-Phase Clinical Trials

Written by ι Stock Market Media Group Staff — March 3, 2014

Nuvilex (OTCQB: NVLX) investors who have patiently waited for the R&D biotech to reach a point where late-phase clinical trials were a reality, are probably relishing these truly exciting times after a Chicago-based institutional investor committed to fund $27 million dollars toward the company’s clinical trials in advanced inoperable pancreatic cancer.  Leading up to the aforementioned clinical trials, investors can expect to see a list of milestone developments unfold, and for ...

Read More →
0
Page 1 of 7 12345...»
ContactUs.com